Yumin Zhang

Key Laboratory Of Virology And Biosafety
Wuhan, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir.

SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir.

Journal: Journal of virology
Published: April 27, 2026

The oral nucleoside analogue inhibitor VV251 effectively inhibits coinfection by respiratory syncytial virus and influenza A virus.

The oral nucleoside analogue inhibitor VV251 effectively inhibits coinfection by respiratory syncytial virus and influenza A virus.

Journal: Journal of virology
Published: April 21, 2026

Recent progress in anti-Chikungunya virus drug discovery: Focus on the viral life cycle and direct-acting antivirals.

Recent progress in anti-Chikungunya virus drug discovery: Focus on the viral life cycle and direct-acting antivirals.

Journal: Virologica Sinica
Published: February 28, 2026

The oral nucleoside drug VV116 is a promising candidate for treating Nipah virus infection.

The oral nucleoside drug VV116 is a promising candidate for treating Nipah virus infection.

Journal: Emerging microbes & infections
Published: November 19, 2025

Investigation of a clinical trial drug VV261 as a potent antiviral candidate against Chikungunya virus.

Investigation of a clinical trial drug VV261 as a potent antiviral candidate against Chikungunya virus.

Journal: Signal transduction and targeted therapy
Published: September 25, 2025

An orally available 4'-fluorouridine prodrug inhibits SFTSV and LCMV infection.

An orally available 4'-fluorouridine prodrug inhibits SFTSV and LCMV infection.

Journal: Journal of virology
Published: September 16, 2025

Structure-Based Development of Ultra-Broad-Spectrum 3C-Like Protease Inhibitors.

Structure-Based Development of Ultra-Broad-Spectrum 3C-Like Protease Inhibitors.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: July 04, 2025

Development of Orally Bioavailable Octahydroindole-Based Peptidomimetic Derivative as a Broad-Spectrum Inhibitor against HCoV-OC43 and SARS-CoV-2.

Development of Orally Bioavailable Octahydroindole-Based Peptidomimetic Derivative as a Broad-Spectrum Inhibitor against HCoV-OC43 and SARS-CoV-2.

Journal: Journal of medicinal chemistry
Published: May 22, 2025

Discovery and mechanistic insights of dibenzoylmethane as a broad spectrum inhibitor of coronavirus.

Discovery and mechanistic insights of dibenzoylmethane as a broad spectrum inhibitor of coronavirus.

Journal: PLoS pathogens
Published: January 25, 2025

Design, Synthesis, and Biological Evaluation of Peptidomimetic Tetrahydropyrrole Spirodihydroindolones as SARS-CoV-2 3CL Protease Inhibitors.

Design, Synthesis, and Biological Evaluation of Peptidomimetic Tetrahydropyrrole Spirodihydroindolones as SARS-CoV-2 3CL Protease Inhibitors.

Journal: ACS medicinal chemistry letters
Published: December 31, 2024

Substrate recognition and cleavage mechanism of the monkeypox virus core protease.

Substrate recognition and cleavage mechanism of the monkeypox virus core protease.

Journal: Nature
Published: October 08, 2024

Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CLpro Inhibitors as anti-SARS-CoV-2 Drug Candidate.

Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CLpro Inhibitors as anti-SARS-CoV-2 Drug Candidate.

Journal: Journal of medicinal chemistry
Published: July 29, 2024
Showing 1-12 of 27

Last Updated: 09/26/2026